Cemiplimab (PDCD1/PD1/CD279) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-907-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG4-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
REGN-2810,SAR-439684,cemiplimab-rwlc
Background:
Cemiplimab is fully human PD-1 antibody. The first indication for marketing application is metastatic / local advanced squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy targeting the PD-1 pathway that can help the immune system fight cancer cells.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Homo sapiens / PDCD1/PD1/CD279 [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.